Recent development of molecular-targeted drugs in lung cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Advanced malignancies are increasingly treated with molecular targeted drugs.
• Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) show efficacy in EGFR mutation-positive lung cancer patients.
• Bevacizumab, an anti-vascular endothelial growth factor (VEGF) antibody, improves outcomes in non-squamous cell lung cancer when combined with chemotherapy.

Purpose of the Study:

• To review recent advancements in molecular targeted drugs for lung cancer.
• To emphasize the clinical application of novel therapies beyond EGFR-TKIs and bevacizumab.
• To highlight the importance of molecular classification in guiding lung cancer treatment.

Main Methods:

• Literature review of recent developments in molecular targeted therapies for lung cancer.
• Analysis of clinical applications and efficacy of EGFR-TKIs and bevacizumab.
• Discussion of evolving lung cancer classification based on molecular biology.

Main Results:

• EGFR-TKIs are effective in selected EGFR mutation-positive lung cancer patients.
• Bevacizumab combined with cytotoxic drugs enhances response rates and progression-free survival in advanced non-squamous cell lung cancer.
• The field of lung cancer treatment is rapidly evolving with new molecular targets.

Conclusions:

• Molecular targeted therapies, including EGFR-TKIs and bevacizumab, represent significant progress in advanced lung cancer treatment.
• Biomarker-driven patient selection is essential for maximizing treatment success.
• Continued research into novel molecular targets and their clinical applications is vital for improving lung cancer outcomes.